TOPIC: General Topics: CAPA
Identification: The CAPA process begins with the identification of issues or non-conformities. This can be done through customer complaints, internal audits, product inspections, or any other means of detecting deviations from established standards.
Investigation: Once an issue is identified, a thorough investigation is conducted to understand the root cause(s). Techniques like the 5 Whys, Fishbone (Ishikawa) diagrams, and fault tree analysis are commonly used during this stage to dig deeper into the problem.
Action Plan: Based on the investigation findings, an action plan is formulated to address the root cause(s) of the issue. This plan includes specific steps to correct the current problem and prevent its recurrence in the future.
Implementation: The proposed corrective and preventive actions are put into action, ensuring that the necessary changes are made to the processes, products, or services.
Monitoring: It is essential to monitor the effectiveness of the implemented actions to ensure they are achieving the desired outcomes. This step often involves using Key Performance Indicators (KPIs) to measure progress.
Verification: To verify the effectiveness of the CAPA process, follow-up checks are conducted to confirm that the issues have been resolved, and preventive actions are in place.
CAPA Requirements – The Regulations Behind the Need
In the life sciences industry, several regulations and standards mandate the implementation of Corrective and Preventive Action (CAPA) processes to ensure product quality, safety, and compliance. Some of the key regulations that require CAPA in life sciences include:
- Current Good Manufacturing Practice (cGMP) Regulations: The cGMP regulations are a set of guidelines and requirements established by various health authorities, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). These regulations apply to pharmaceuticals, biologics, medical devices, and other life sciences products. CAPA is a fundamental aspect of cGMP compliance and is essential for identifying and addressing deviations and non-conformities related to product quality.
- ISO 13485 – Medical Devices – Quality Management Systems: ISO 13485 is an international standard that specifies requirements for quality management systems for medical device manufacturers. CAPA is a crucial component of this standard, ensuring that companies take appropriate actions to address quality issues and prevent their recurrence.
- ISO 14971 – Medical Devices – Application of Risk Management to Medical Devices: ISO 14971 outlines requirements for risk management in medical device development and manufacturing. CAPA is closely linked to risk management, as it helps in identifying and addressing potential risks associated with products and processes.
- 21 CFR Part 211 – Current Good Manufacturing Practice for Finished Pharmaceuticals (cGMPs for Finished Pharmaceuticals): This regulation, issued by the FDA, outlines cGMP requirements specific to the pharmaceutical industry. CAPA is a key component of compliance with Part 211, ensuring that pharmaceutical companies maintain product quality and safety.
- 21 CFR Part 820 – Quality System Regulation (QSR) for Medical Devices: The FDA’s QSR establishes requirements for medical device manufacturers to ensure the quality of their products. CAPA is a central element of QSR, helping manufacturers address product and process issues and enhance overall quality.
- EU Medical Device Regulation (MDR) and In-Vitro Diagnostic Regulation (IVDR): The MDR and IVDR are regulatory frameworks for medical devices and in-vitro diagnostic medical devices in the European Union. These regulations require manufacturers to implement CAPA processes to address any non-conformities and improve device safety and performance.
- Pharmacovigilance Requirements: Pharmaceutical companies are required to have robust pharmacovigilance systems to monitor and report adverse events related to their products. CAPA is instrumental in addressing safety concerns and taking appropriate actions to prevent future adverse events.
- FDA Quality System Regulation (QSR) for Combination Products: Combination products, which involve a combination of drugs, devices, or biological products, must comply with the FDA’s QSR. CAPA is an essential component of QSR compliance, addressing quality issues related to combination products.
Compliance with these regulations and standards is essential for life sciences companies to maintain the safety and efficacy of their products and ensure the well-being of patients and consumers. Implementing effective CAPA processes is not only a regulatory requirement but also a best practice to continuously improve product quality and enhance patient safety.
MEDVACON and our team of experts can help you identify which regulations apply to your business and how to achieve the optimal CAPA process.
